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Gamma secretaseThere has been no extensive characterization of the effects of Ginsenoside Rg1, a pharmacological active
component puriﬁed from the nature product ginseng, in an Alzheimer's disease mouse model. The well-
characterized transgenic Alzheimer disease (AD) mice over expressing amyloid precursor protein (APP)/
Aβ (Tg mAPP) and nontransgenic (nonTg) littermates at age of 6 and 9 months were treated with Rg 1
for three months via intraperitoneal injection. Mice were then evaluated for changes in amyloid pathology,
neuropathology and behavior. Tg mAPP treated with Rg1 showed a signiﬁcant reduction of cerebral Aβ
levels, reversal of certain neuropathological changes, and preservation of spatial learning and memory,
as compared to vehicle-treated mice. Rg1 treatment inhibited activity of γ-secretase in both Tg mAPP
mice and B103-APP cells, indicating the involvement of Rg1 in APP regulation pathway. Furthermore,
administration of Rg1 enhanced PKA/CREB pathway activation in mAPP mice and in cultured cortical
neurons exposed to Aβ or glutamate-mediated synaptic stress. Most importantly, the beneﬁcial effects
on attenuation of cerebral Aβ accumulation, improvement in neuropathological and behavioral changes
can be extended to the aged mAPP mice, even to 12–13 months old mice that had extensive amyloid
pathology and severe neuropathological and cognitive malfunction. These studies indicate that Rg1
has profound multi-faced and neuroprotective effects in an AD mouse model. Rg1 induces neuroprotection
through ameliorating amyloid pathology, modulating APP process, improving cognition, and activating
PKA/CREB signaling. These ﬁndings provide a new perspective for the treatment of AD and demonstrate
potential for a new class of drugs for AD treatment.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD) is deﬁned by the progressive impairment
in memory and cognition and by the presence of two major patho-
logical hallmarks, accumulation of β-amyloid protein (Aβ) and forma-
tion of neuroﬁbrillary tangles composed of hyperphosphorylated tau.
Aβ, a key constituent of amyloid plaque, is a neurotoxic peptide that
contributes to neuronal, synaptic and cognitive malfunction in an Aβ
rich environment found in human AD and the AD mouse model.
Thus, strategies that reduce Aβ levels in the brain and improveology and Toxicology, Higuchi
nt Ave, Lawrence, KS 66047,
Lue), shidu@ku.edu (S.S. Yan).
l rights reserved.cognitive function are critical for prevention and/or halting of AD
progression.
Ginseng, a drug used in traditional Chinese medicine that has a
wide range of pharmacological effects, has been empirically used to
alleviate many ailments, particularly those associated with aging
and memory deterioration [1–3]. Rg1, one of the bioactive com-
pounds in ginseng crosses the blood–brain barrier [4]. Several studies
provide evidence of its neurotrophic, neuroprotective and anti-aging
properties [5–8]. Pretreatment with Rg1 improved viability in cells
injured by Aβ, reduced the levels of intracellular Aβ 1–42, and atten-
uated the activation of caspase-3 and apoptosis [9–11]. Furthermore,
recent studies demonstrated that administration of ginsenosides
including Rg 1 reduced cerebral Aβ in Tg 2576 mice [12], an AD
mouse model as well as aging mice [13]. However, the mechanisms
underlying Rg1-involved attenuation of Aβ accumulation and im-
provement in learning and memory in an Aβ-rich environment
remain unclear.
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teolysis of the Type I membrane protein, amyloid precursor protein
(APP) [14]. Aβ formation involves the sequential cleavage of amyloid
precursor protein (APP) by two proteases, the β- and γ-secretases
[15]. β secretase cleaves APP at the N-terminus to form APP-CTF-β
(C99), which is subsequently cleaved by a multi-protein γ-secretase
complex that results in generation of the Aβ peptide and a smaller
APP-CTF-γ. It follows then that γ secretase is a potential prime drug
target for the treatment of Alzheimer's disease. However, it is unclear
whether Rg1 is involved in regulation of the APP process via γ
secretase.
Tg mAPP mice have been well characterized with respect to
mitochondrial function and neuropathological, behavioral and
electrophysiological endpoints [16–23]. The strengths of this model
include the rapid accumulation of Aß (started at 2–4 months; plaque
formation at 6 months), decreased density of presynaptic terminals,
abnormalities in synaptic, electrophysiological and behavioral
changes. Importantly, there is no report on studying Rg1 in this
model with overexpression of human Aβ including APP process and
neuropathological changes. Thus, it would be essential and logical
for choosing an aggressive AD model to determine the impact of
Rg1 on neuronal and cognitive function.
The goals of the present study are: 1) to fully assess the effects of
Rg 1 on cerebral Aβ accumulation, amyloid pathology, neuronal
function, and learning/memory capacity in a well-characterized
mouse model for AD; and 2) to elucidate the pathways affected by
Rg1 that suppress Aβ production and improve neuronal and cognitive
function. Results generated from the study would provide substantial
evidence for preclinical translation study of Rg1 as a new therapeutic
agent for prevention of AD and slowing of the disease process.
2. Material and methods
2.1. Tg mice and cell culture
All animal experiments were approved by the Institutional Animal
Care and Use Committee of Columbia University and conformed to
the guidelines outlined in the National Institutes of Health Guide for
Care and Use of Laboratory Animals (NIH Pub. No. 85–23, 1996).
Transgenic (Tg) mice with neuronal overexpression of a mutant
human form of amyloid precursor protein (Tg mAPP, J-20 line, origi-
nally provided by Dr. Lennart Mucke, University of California, San Fran-
cisco) driven by the platelet-derived growth factor (PDGF) B-chain
promoter were used in this study. These Tg mice are a well-
established mouse model for the Alzheimer disease and exhibit many
features of AD neuropathology [16,18,24], and have been used in previ-
ously published studies [17–21,25]. Tg mice were divided into four
groups: mAPP and nonTg littermate control mice treated with vehicle
(PBS) or Rg1 in PBS, 5–7 mice per group. Rg1 (10 mg/kg based on the
previous study [13]) was intraperitoneally injected daily, starting at
age of 6 or 9–10 months for a period of three months.
For cellular studies, cortical neurons were prepared from mouse
embryos at day 16 of gestation. Rat neuroblastoma B103 cells stably
expressing human wild-type (wt) APP (B103-wtAPP) were kindly
provided by Tony Wyss-Coray [26].
2.2. Reagents
Ginseng Rg1 (molecular weight 800, purity 98%) was provided by
the Department of Biochemistry of Jilin University, China.
2.3. Immunohistochemistry
The acetycholinesterase (AChE) activity was determined by the
change in AChE density (area occupied) in brain region (entorhinal
cortex). After 6 min of perfusion with saline, mice brains weredivided sagittally in half; one half was immersed in paraformalde-
hyde (4%) for 26 h. Serial vibratome sections (20 μm, two sections
from each mouse) were incubated with the mixture of the two me-
diums: (A) 5 mg of acetylthiocholine iodide, 6.5 mL of 0.1-mmol/L ac-
etate buffer (pH 6.0), 0.5 ml of 30-mmol/L copper sulfate, 1.0 ml of
distilled water, and 0.2 mL of 4-mmol/L iso octamethyl pyropho-
sphoramide (iso OMPA); and (B) 1.0 ml of 5-mmol/L potassium ferri-
cyanide at 37 °C for 5 min and rinse with tap water for 10 s. Following
this, they were developed with freshly prepared 3-3′ diamino
benzidine tetrahydrochloride (25 mg in 100mL of 0.05-mol/L
phosphate buffer [pH 7.0]), containing 0.015% H202 for 5 min at
room temperature. Afterward, wash with tap water, dehydrate and
mount. Acetylcholine esterase (AChE) activity was analyzed
histochemically by the area occupied by AChE-positive staining
neurites in the entorhinal cortex (the area in which cholinergic neurite
is prominent) in the brain usingMetaMorph software as previously de-
scribed [18,27]. Sections were also reacted with anti-Aß antibody 3D6
(dilution 1:1000) to identify Aß deposits. Areas with Aß plaques were
analyzed using MetaMorph software evaluating multiple sections of
the same level in each animal group. To ensure objective assessments
and reliability of the results, brain sections from mice in any given ex-
periment were blind coded and processed in parallel. Codes were
revealed only after the analysis was completed.
2.4. Aβ ELISA
The brain tissue was extracted with 8 volumes of guanidine-Tris
buffer (5.0 M Guanidine HCl/50 mM Tris–HCl, pH 8.0). The homoge-
nates were mixed for 3–4 h at room temperature. The speciﬁc
human Aβ1-40 and human Aβ1-42 levels in brain tissue and cultured
medium of B103-wtAPP cells derived from Rg1 (5 μM or 10 μM) or
vehicle treatment for 48 h were measured by ELISA kit following the
manufacturer's instructions (Invitrogen, CA).
2.5. γ-Secretase activity
γ-Secretase activity was measured as previously described [28].
Freshly dissected mouse cerebral cortex was homogenized in homog-
enization buffer (10 mM MOPS, pH 7.0, 10 mM KCL, 1× complete
protease inhibitor cocktail) and centrifuged at 2500 rpm for 15 min
at 4 °C. The supernatant was collected and centrifuged at 14000 rpm
for 20 min at 4 °C. The pellet was rinsed once in homogenization
buffer and then resuspended in assay buffer (150 mM sodium citrate,
pH 6.4, 1× complete protease inhibitor cocktail, protein concentration
4 μg/μl). Samples were incubated at 37 °C for 2 h, and then subjected
to Western blot. The APP-CTF antibody was used for APP-CTF-γ
(6 kDa) identiﬁcation (Calbiochem, USA). B103-wtAPP cells treated
with Rg1 or vehicle were processed similar to tissue samples.
2.6. PKA activity and phosphor-CREB (p-CREB) and total-CREB (T-CREB)
Cultured cortical neurons were treated with Rg1 and/or oligomeric
Aβ1-42, and then harvested in lysis buffer (20 mM MOPS, 50 mM
β-glycerolphosphate, 50 mM sodium ﬂuoride, 1 mM sodium vana-
date, 5 mM EGTA, 2 mM EDTA, 1% NP40, 1 mM dithiothreitol (DTT),
1 mM benzamidine, 1 mM phenylmethane-sulphonylﬂuoride (PMSF)
and 10 μg/mL leupeptin and aprotinin). PKA activity was measured
using a PKA Kinase Activity Assay Kit (Stressgen, Ann Arbor,
Michigan, USA), according to the manufacturer's instructions.
Levels of p-CREB and T-CREB in cultured cortical neurons were
analyzed using previous described methods [29]. Brieﬂy, cortical
neurons were treated with Rg1 and/or oligomer Aβ1-42, and then
exposed to 50 μM glutamate (from Sigma) in a salt medium (contain-
ing 119 mMNaCl, 5 mM KCl, 2 mM CaCl2 20 mMHepes, 1 μM glycine,
300 mM glucose) for 15 min (ginsenoside Rg1 and/or Aβ1-42 were
added to the culture medium to maintain stable concentration
Fig. 1. Effect of Rg1 on Aβ accumulation. Panels A and B. ELISA used for the measure-
ment of Aβ 40 (left) and Aβ 42 (right) in the hippocampus of 9 (A) and 12–13
(B) month old Tg mAPP mice injected intraperitoneally with Rg1 (10 mg/kg) daily con-
tinuously for 3 months or with vehicle. Aβ 40 and Aβ 42 levels were signiﬁcantly
decreased in Rg1 injection group as compared to vehicle. Panel C. Immunostaining
for Aβ plaque using Aβ antibody (3D6) in 9 month old Tg mAPP mice injected with
Rg1 or vehicle. Representative sections showed Aβ deposits from Tg mAPP mice
injectedwith Rg1(left) orwith vehicle (right). Panel D. Quantiﬁcation of area (percentage)
occupied by Aβ plaques in the indicated Tgmice. N=5–6mice per group. Scale bar 30 μm.
Fig. 2. Effect of Rg1 on γ-secretase activity in the brain of Tg mAPP mice and nonTg
mice. Panel A. Densitometry of APP C-terminal fragment cleavage by gamma secretase
(APP-CTF-γ) from indicated Tg mice at age of 12–13 months. Decreased γ-secretase ac-
tivity in the cerebral cortex assessed by APP-CTF-γ from membrane-associated APP in
Tg mAPP mice injected with Rg1 as compared to Tg mAPP mice injected with vehicle.
Panel B. Representative Western blots of brain extracts for full length APP, APP-CTF-γ
and β-actin in the indicated mice. Rg1 did not affect total APP expression, whereas
the cleavage products of APP-CTF-γ generated from membrane-bound APP were di-
minished in Rg1-treated mAPP mice. N=3–5 mice per group.
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blotting with speciﬁc antibodies to p-CREB or T-CREB (1:1,000
dilution, Cell Signaling technology, Danvers, MA, USA). Levels of
p-CREB/T-CREB in the brains were measured using p-CREB and T-
CREB ELISA kits (Invitrogen).
2.7. Behavioral studies
Spatial learning and memory was evaluated using the radial arm
water maze as previously described [18,19,21,25]. Brieﬂy, the mouse
started the task from a different randomly chosen arm for each trial.
The mouse could not use its long-term memory of the location of
the platform on previous days, but had to rely on the short-term
memory of its location on the day in question based on spatial clues
that were present in the room. Each trial lasted one minute and errors
were counted each time the mouse entered the wrong arm or needed
more than 20 s to reach the platform. After each error, the mouse was
gently pulled back to the start arm for that trial. At the end of the trial,
the mouse remained on the platform for 30 s. After four consecutive
trials, the mouse was placed in its home cage for 30 min, then
returned to the maze and administered a retention trial. Testing
was considered complete when wild-type mice reached an
asymptotic performance (below 2 errors on trials 4 and 5). The gen-
erally took about 10–14 training days. The scores for each mouse on
the last three days of testing were averaged and used for statistical
analysis. The investigators were blinded to mouse genotypes and ex-
perimental conditions.
2.8. Statistical analysis
One-way ANOVA was used for repeated measure analysis fol-
lowed by Fisher's Protected Least Signiﬁcant Difference for post-hoc
comparisons. STATVIEW computer software was utilized. Results
were expressed as mean±Standard Error of the Mean (SEM).
3. Results
3.1. Effect of Rg1 on Aβ accumulation
Tg mAPP mice and nonTg littermates at age of 6 months (begin-
ning Aβ accumulation in the brain) and 9–10 months (severe amyloid
pathology, late stage) were treated with Rg1 for 3 months to deter-
mine the effect of Rg1 on early and late stage AD pathology and to
examine whether Rg1 is able to reverse existing AD pathology. After
3 month of Rg1 treatment, levels of Aβ1-40 and Aβ1-42 including
soluble and insoluble Aβ were signiﬁcantly lower in hippocampus
of Rg1-treated mAPP mice than in vehicle-treated mice (Fig. 1A).
Intriguingly, similar results were obtained from mAPP mice treated
with Rg1 from 9–10 to 12–13 months of age (Fig. 1B). Consistent
with this result, Aβ plaque loads were signiﬁcantly reduced in
cerebral cortex including hippocampus of Rg1-treated mAPP mice,
whereas vehicle-treated mAPP mice displayed expected plentiful Aβ
deposits in the brains. Quantiﬁcation of Aβ plaque load revealed
that the area covered by Aβ deposits in the brains of Rg1-treated
mAPP mice was signiﬁcantly reduced compared to those of vehicle-
treated mAPP mice (Fig. 1C–D; Pb0.01).
3.2. Effect of Rg1 on γ secretase activity
To probe the mechanism by which Rg1 reduces Aβ accumulation,
we ﬁrst measured γ-secretase activity in brain tissue using an
established enzymatic assay based on carboxyl terminal fragment
detection APP-CTF-γ (6 kDa) formation from membrane bound APP
[28], which is an index of γ-secretase activity. Measurement of APP
in the cortex of the mice showed no differences in full length APP in
mAPP mice with and without Rg1 treatment. However, the intensityof immunoreactive bands corresponding to 6 kDa APP-CTF-γ was
signiﬁcantly reduced in Rg1-treated mAPP brains as compared with
those from vehicle-treated mAPP brains, indicating that γ-secretase
activity was signiﬁcantly diminished (Fig. 2A–B; Pb0.05). No signiﬁ-
cant differences were found in full length APP among Rg1-treated
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for β-actin veriﬁed an equal amount protein loading in each groups of
mice (Fig. 2B).
Second, to investigate the direct effect of Rg1 on γ-secretase, rat
neuroblastoma cells (B103) stably transfected with wild-type APP
(wtAPP) were incubated with Rg1 (5 μM and10μM) for 48 h, followed
by analysis of APP-CTF-γ levels in the cell lysate by immunoblotting
and measurement of Aβ levels in cell-free culture medium. Aβ levels
were signiﬁcantly decreased in cultured medium of Rg1-treated cells
compared to those in the vehicle-treated group (Fig. 3A; *Pb0.01; and
#Pb0.05 compared to the vehicle). Importantly, the intensities of
APP-CTF-γ immunoreactive bands in the cell lysate were signiﬁcantly
decreased in Rg1-treated B103-wtAPP cells compared to those with-
out Rg1 treatment (Fig. 3B and D, APP-CTF-γ: Pb0.01). Remarkably,
Rg1 treatment almost abolished γ-secretase activity as shown by
prominently diminished 6 kDa APP-CTF-γ immunoreactive bands by
3–4 folds. There are no signiﬁcant differences in levels of APP-CTF-γ
in cells exposed to 10 μM Rg1 compared to cells exposed to 5 μM
(P=0.33) though Rg1 5 μM appears lower than 10 μM in panel D.
Similarly, levels of Abeta 40 in cells treated with 10 μM Rg1 were
comparable to the cells treated with 5 μM Rg1 (P=0.298). Fig. 3B
shows the representative immunoreactive bands of the various
groups. Since B103-wtAPP cells used in our experiments are over-
expressed wild-type APP gene, whereas nonTg mice express endoge-
nous wtAPP, the gamma secretase activity was higher in B103-wtAPP
cells than that in nonTg mice. This could explain that the activity of
gamma-secretase appears to be profoundly suppressed in B103-wt
APP cells as compared to that in nonTg mice. There were no differ-
ences in full length APP for Tg mice or B103-wtAPP cells with and
without Rg1 treatment (Figs. 2B and 3B–C), suggesting that Rg1
does not interfere with APP generation/production. These in vitro
results support the observations made for in vivo Rg1-treated mAPP
mice both of which indicate that Rg1 treatment decreased
γ-secretase activity, which is responsible for Aβ production.
3.3. Effect of Rg1 on neuropathologic development in Tg mAPP mice
In view of decreased Aβ accumulation in Rg1-treated mAPP brain,
we next determined whether Rg1 treatment could reverseFig. 3. Effect of Rg1 on γ-secretase activity in neuronal cells expressing wt APP. Panel A.
Aβ ELISA used for measurement of Aβ1-40 and Aβ1-42 levels in the supernatant of
cultured neuronal cells (B103) stably expressed wild-type APP (wtAPP) in the
presence of Rg1 (5 and 10 μM) or vehicle for 48 h. Panel B. Representative Western
blots of cultured B103-wtAPP cells for APP and APP-CTF-γ, showing decreased APP-
CTF-γ generated from membrane associated APP because of reduced γ-secretase
activity in cultured B103-wtAPP cells treated with 5 μM or 10 μM Rg1 for 48 h. Panels
C–D. Densitometry of APP (C) and APP-CTF-γ (D) immunoreactive bands in cells
with and without treatment of Rg1. (*Pb0.01, #Pb0.05 compared to those from
vehicle-treated B103-wtAPP cells).neuropathological changes in mAPP brain. Since diminished density
of cholinergic ﬁbers and synapses is associated with AD-like patholo-
gy [30,31] and because density of acetylcholinesterase (AChE)-posi-
tive neurite was signiﬁcantly decreased in the AD-affected brain
regions of mAPP mice [18,27], we examined AChE activity. AChE ac-
tivity was determined histochemically and reported as the area occu-
pied by positively staining neurites in the entorhinal cortex (the area
in which cholinergic neurite is predominant) in brain. As previously
reported [18,27], at the 12–13 months of age, mAPP mice exhibited
decreased levels of AChE-positive neurites in the entorhinal cortex
compared to nonTg mice (Fig. 4; Pb0.01). Such decreases in AChE-
positive ﬁbers in mAPP brain were signiﬁcantly reversed by the
administration of Rg1. A representative example of AChE histochem-
ically stained sections of entorhinal cortex from each group of mice is
shown in the lower panel of Fig. 4. There were no differences between
Rg1-treated and vehicle-treated nonTg mice, indicating no effect of
Rg1 on neuronal structure and function. These data indicate a
protective effect of Rg1 on Aβ-induced neuropathologic alterations
in mAPP mice.
3.4. Administration of Rg1 improves learning/memory in Tg mAPP mice
Based on our observations that Rg1 treatment reduced AD-type
amyloidosis and neuropathological changes, we then explored the
possibility that Rg1 could improve cognitive ability even in aged
mAPP mice, whose behaviors were severely impaired by the age of
9–13 months. Using the radial arm water maze, known to detect
hippocampal-dependent learning and memory deﬁcits, we tested
whether Rg1 treatment improves learning and memory. At 9–
13 months of age, vehicle-treated mAPP mice displayed impaired
spatial learning memory for platform location between trials
(average of about 4–6 errors by trial 4 and retention test). In
contrast, Rg 1-treated mAPP mice demonstrated good spatial
memory, ﬁnding the hidden platform more rapidly with increasing
trials as compared to vehicle (Fig. 5; Pb0.01 at age 9–10 months,
Pb0.05 at age12–13 months). Remarkably, Rg1 treatment for three
months (from age of 6 months) completely reversed or largely
improved spatial learning/memory as shown by ~2–3 errors on
the maze compared to vehicle-treated mAPP mice (~ 4–6 errors by
trials 4 or 5) (Fig. 5A–B). Further, Rg1 treatment markedly improved
spatial learning/memory even in aged mAPP mice with severely
impaired behavior and neuropathological impairment (Fig. 5B).
Rg1 did not affect normal behavior as demonstrated by a good
performance in Rg 1 treated nonTg mice. Four groups of Tg mice
showed no difference in their speed of swimming or in the time
required to reach the platform in the visible platform test (dataFig. 4. Effect of Rg1 on neuropathological ﬁndings in Tg mAPP mice. AChE activity was
determined histochemically in the entorhinal cortex of the indicated mice groups at
12–13 months of age. Quantiﬁcation of density of AChE-positive neurites in the
entorhinal cortex of hippocampus in the indicated Tg mice (* Pb0.01 vs. other groups
of mice, n=4–6 mice/group). Representative images for AChE staining in the entorhinal
cortex of the indicated mice are shown in the lower panel. Scale bar=5 μm.
Fig. 5. Effect of Rg1 on spatial learning/memory in Tg mAPP mice. Spatial/learning
memory was tested with the radial arm water maze at 9–10 months (left) and
12–13 months (right) of age in the indicated groups of mice (n=5–8 male
mice/group). Trials 1–4 denote acquisition trials and trial 5 denotes retention
trial. Tg mAPP mice injected with Rg1 showed improved spatial learning memory
as compared to Tg mAPP mice injected with vehicle. *Pb0.01, # Pb0.05 vs. Tg
mAPP+vehicle.
Fig. 6. Rg1 activation of PKA and p-CREB pathway. Panel A. PKA activity was determine
months (started at 9 month old), respectively. Panel B. ELISA was performed to measure
graphs of Fig. 6B represented fold-increased phosphor-CREB normalized to total of CREB
nonTg mice and #Pb0.05 vs. vehicle-treated Tg mAPP mice. Panel C. Ginsenoside Rg1 a
cortical neurons were preincubated with ginsenoside Rg1 (0, 2.5, 5, 10 μM) for 1 h, and
PKA activity in cell lysates was measured and data were expressed as fold-increased c
#Pb0.01 vs. neurons with 5.0 μM Aβ1-42 treatment. Panel D. Modulation of glutamate
ulated strongly by treatment with 50 μM glutamate (Glut) for 15 min. Pretreatment wit
the preincubation of 2.5/5/10 μM ginsenoside Rg1 (Rg1-Aβ-Glut). Data are shown as th
repeated at least three times.
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memory improvement is a consequence of Rg1 treatment in mAPP
mice.3.5. Rg1 activation of PKA and phosphorylation of CREB
We next explored the possible mechanisms underlying im-
proved neuronal and cognitive function and apparent protection in
Rg1-treated mAPP mice, compared to ﬁndings in vehicle-treated
mAPP mice. cAMP-dependent protein kinase (PKA) is critical for
hippocampal-dependent long-term memory and for long-lasting
potentiation (LTP) [29,32–38]. Activation of the PKA intracellular
signaling pathway has been implicated in synaptic facilitation and
enhanced memory of age-related [33,36,37,39,40] and Aß-induced
deﬁcits [29,32–34,38]. Aβ is known to perturb signal transduction
pathways, including that of PKA/CREB, leading to changes in synap-
tic plasticity and memory [29,33,34]. We therefore measured PKA
activity and its downstream target, phosphorylated CREB (pCREB)
in brain extracts. As shown in Fig. 6A, 12–13 month-old mAPP
mice displayed signiﬁcantly decreased PKA activity as compared to
nonTg littermates (Pb0.01 vs. nonTg mice). However, Rg1 treatment
for 3 months (from age 9–10 months to 12–13 month) completely
restored PKA activity. Because CREB phosphorylation depends on PKA
activity, we next measured pCREB levels in cortex extracts by ELISA.
mAPP mice showed signiﬁcantly decreased CREB phosphorylation at
Ser 133 compared to nonTg littermates, whereas levels of CREB
phosphorylation at serine 133 were signiﬁcantly greater in Rg1-
treated Tg mAPP mice than vehicle-treated Tg mAPP mice (Fig. 6B;
*Pb0.01 vs. nonTg+vehicle, # Pb0.05 vs. mAPP+vehicle). Total
CREB levels were similar in Rg1-treated and vehicle-treated mAPP
mice.
To determine the direct effect of Rg1 on PKA activation and CREB
phosphorylation, we measured PKA activity and CREB phosphorylationd in brain extracts of the indicated Tg mice treated with Rg1 or vehicle for three
levels of phosphor- and total-CREB in the cortex of the indicated Tg mice. The bar
. There was no signiﬁcant change in the total of CREB. * pb0.05 vs. vehicle-treated
ttenuated the decrease in PKA activity induced by oligomeric Aβ1-42. The cultured
then oligomeric Aβ1-42 (5 μM) or vehicle was added to the cells. Two hours later,
ompared to vehicle-treated cells. Results are shown as the mean±SEM. *Pb0.05,
-stimulated CREB phosphorylation by oligomeric Aβ1-42. Phosphorylation is stim-
h 5 μM Aβ for 2 h results in a decrease in pCREB /T-CREB. This effect is opposed by
e mean±SEM. #Pb0.01 vs. neurons with 5.0 μM Aβ1-42 treatment. Studies were
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(2.5, 5, and 10 μM) in the presence of Aβ. As previously reported,
treatment of cultured neurons with oligomer Aβ depressed PKA
activity and inactivated CREB phosphorylation in response to
glutamate stimulation. PKA activity was signiﬁcantly decreased in
neurons treated with Aβ compared to those from vehicle-treated
neurons. Notably, Rg1 abolished Aβ-induced suppression of PKA
activity in a dose-dependent manner. Similarly, in the presence of
Aβ, pCREB decreased in response to glutamate stimulation; the
addition of Rg1 suppressed Aβ-induced inhibitory effects on pCREB in
a dose-dependent manner (Fig. 6C–D; * Pb0.05, # Pb0.01). These
results strongly suggest that inhibition of the PKA/CREB pathway
underlies the effects of Aβ on synaptic function; further Rg1 enhances
PKA activity and CREB phosphorylation, and may be responsible for
protection against Aβ-induced neuronal dysfunction and cognitive
decline in mAPP mice.
4. Discussion
In the present study, we established that Rg1 treatment protects
against Aβ-mediated abnormalities in a well-characterized AD
mouse model over expressing Aβ. Rg1 treatment reversed deleterious
effects in mAPP mice, and even in aged mAPP mice that had severe
neuropathological changes and impaired learning/memory.
First, we demonstrated a role of Rg-1 on regulation of γ-secretase,
a potential mechanism of Rg1-mediated reduction in Aβ accumula-
tion in brain both in vitro Aβ-rich neuronal culture and in vivo
mAPP mice over expressing Aβ. Second, we showed a protective
effect of Rg1 on Aβ-induced neuropathological changes in mAPP
mice as shown by increased AChE-positive ﬁbers in mAPP brain
upon Rg1 treatment. Third, using different transgenic AD mouse
model, an aggressive model of beta-amyloid pathology, we were
able to observe the protective effects of Rg1 as previously described
in the non-AD mouse model (SAMP8 mice) [12,13,41]. These repro-
ducible results in particular from a different transgenic AD mouse
model provide the additional evidence of the protective effects of
Rg1 on Aβ-induced amyloid pathology and impaired cognitive func-
tion, which will signiﬁcantly strengthen and support the signiﬁcance
of Rg1 on the clinical translation application in the future.
We investigated the possible mechanisms underlying the Rg1
protection noted above. Rg1 treatment signiﬁcantly inhibited γ-
secretase in studies of in vitro cultured neuronal cells and in vivo
mAPP mice overexpressing Aβ. It was previously reported that oral
Rg1 treatment decreased Aβ levels in the brain of Tg 2576 mice
[12], but the underlying mechanism of lower cerebral amyloid
accumulation was unclear. Our results suggest the involvement of
Rg1 in modulation of APP cleavage. APP is cleaved by three secretases
to generate various distinct products. β -secretase cleaves APP at the
N-terminus to form CTF-β, which is subsequently cleaved by γ-
secretase to form Aβ 40 and 42 residues [42]. Therapeutic inhibition
of β- and γ-secretase decreased all forms of Aβ, including the patho-
genic Aβ42. Given that inhibition of γ-secretase decreases Aβ
production, development of compounds that inhibit and/or modulate
γ-secretase activity will represent a rational therapeutic approach for
the treatment of AD. Several groups have shown that γ-secretase
inhibitor treatment results in therapeutic reduction of neurotoxic
Aβ peptides [43,44]. Rg1-mediated reduction of γ-secretase activity
would therefore provide additive protection against Aβ amyloidosis.
Rg1 might also be a promising therapeutic candidate for AD due to
its strong protection and low incidence of adverse effects.
The cAMP-respond element-binding protein (CREB) is important
for learning and memory and may be a core component of the molec-
ular switch that converts memory from short-term to long-term [45].
The major regulator of CREB activity is cAMP-dependent protein
kinase (PKA). Increases in intracellular cAMP activated PKA act to
disassociate the regulatory subunits from the catalytic subunits.Activated PKA moves into the cell nucleus, where it phosphorylates
CREB. Interestingly, recent studies have shown that PKA/CREB-
dependent signaling, which is required for long-term potentia-
tion, is inhibited by sublethal concentrations of Aβ in cultured
hippocampal neurons in mouse models of AD or in human AD
brain [29,33,46–48]. Rg1 treatment increases cAMP levels in adi-
pocytes and prevents memory loss in aged SAMP8 mice through
increased hippocampal antioxidation and up-regulation of
plasticity-related proteins including phosphor-CREB [41]. Taken
together, these studies suggest that Rg1 activates the PKA/CREB
signal transduction pathway thereby contributing to the im-
proved or the retained cognitive function. To date, there is no re-
port on the effects of Rg1 on activation of the PKA/CREB pathway in
an accelerating AD mouse model.
The data presented herein clearly shows that spatial learning/
memory impairment is signiﬁcantly improved in Tg mAPP mice
treated with Rg1. Further, our results demonstrate that Rg1 enhances
the PKA/CREB signaling pathway in an Aβ-rich environment in mAPP
mice aswell as in cultured cells. PKA activity and CREB phosphorylation
play a key role in synaptic function and memory. CREB is a key
molecule in initiation of transcriptional activation of other genes
encoding proteins. It has been proposed that the effect of Aβ on
long term potentiation (a form of synaptic function) and memory
is mediated by the inhibition of phosphorylation of CREB, a
transcription factor that is activated by cAMP-dependent protein
kinase (PKA) activity[29,33]. Acute alterations in dendritic spines
induced by Aβ as well as chronic loss of spine density seen in
mAPP transgenic mice are both reversible by treatments that
restore the cAMP/PKA/CREB signaling pathway [49]. Puzzo et al.
demonstrated that CREB activation ameliorates synaptic function
and memory in a mouse model of amyloid deposition [50]. Therefore,
Rg1-mediated activation of PKA/CREB signal transduction mechanisms
may be responsible for alleviating deﬁcits of learning and memory in
mAPP mice. Aβ can also disrupt multiple signal transduction pathways
including Ca2+-regulated signaling pathways and oxidative stress-
mediated kinase system. The potential effects of Rg1 on these
signaling pathways require for the further investigation.
In summary, our results clearly demonstrate the protective effect
of Rg1 treatment on cerebral Aβ accumulation, neuropathological
change, and impaired learning/memory in a transgenic mouse
model for AD. Notably, Rg1 treatment is able to reverse largely Aβ-
induced deteriorated effects observed in an aged transgenic mouse
model for Alzheimer disease, which exhibits the extensive amyloid
pathology and cognitive decline. The mechanism through which Rg1
regulates APP process via decreased γ-secretase activity and enhances
PKA/CREB signaling may explain its neuroprotective role. Given that
lowering Abeta on its own so far (based on immunization or beta/
gamma secretase inhibitors to suppress Abeta production) does not ap-
pear to be sufﬁcient for attenuating neuronal dysfunction and improving
cognitive function in AD patient, multiple targets such as PKA/CREB or
combination with agonists of neuronal and cognitive function in ad-
dition to lowering Abeta would be therapeutic strategy for AD. Togeth-
er with the previous studies, our data indicate that Rg1 is a potential
therapeutic agent for preventing and halting AD progression.
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